Suppr超能文献

预防性补充青春双歧杆菌 ATTCC 15703 可部分减轻 Balb/c 小鼠而非 C57BL/6 小鼠的过敏性气道疾病。

Prophylactic Bifidobacterium adolescentis ATTCC 15703 supplementation reduces partially allergic airway disease in Balb/c but not in C57BL/6 mice.

机构信息

1 Institute of Environmental, Chemistry and Pharmaceutical Sciences, Department of Pharmaceutics Sciences, Federal University of São Paulo, 09972-270 Diadema, SP, Brazil.

2 Institute of Biomedical Sciences, University de São Paulo, Department of Physiology and Biophysics, Av. Prof. Lineu Prestes, 1524, 05508-000 São Paulo, SP, Brazil.

出版信息

Benef Microbes. 2018 Apr 25;9(3):465-476. doi: 10.3920/BM2017.0073. Epub 2018 Apr 10.

Abstract

Allergic asthma is a chronic disease mainly characterised by eosinophil inflammation and airway remodelling. Many studies have shown that the gut microbiota of allergic individuals differs from that of non-allergic individuals. Although high levels of bifidobacteria have been associated with healthy persons, Bifidobacterium adolescentis ATCC 15703, a gut bacteria, has been associated with allergic individuals in some clinical studies. The relationship between B. adolescentis ATCC 15703 and asthma or allergies has not been well elucidated, and its effect may be dependent on the host's genetic profile or disease state. To elucidate this question, we evaluated the role of preventive B. adolescentis ATCC 15703 treatment on experimental allergic airway inflammation in two genetically different mouse strains, Balb/c and C57BL/6 (B6). Balb/c mice display a greater predisposition to develop allergic responses than B6 mice. Oral preventive treatment with B. adolescentis ATCC 15703 modulated experimental allergic airway inflammation, specifically in Balb/c mice, which showed decreased levels of eosinophils in the airway. B6 mice did not exhibit any significant alterations in eosinophils but showed an increased influx of total leukocytes and neutrophils into the airway. The mechanism underlying the beneficial effects of these bacteria in experimental allergic mice may involve products of bacteria metabolism, as dead bacteria did not mimic the ability of live B. adolescentis ATCC 15703 to attenuate the influx of eosinophils into the airway. To conclude, preventive oral B. adolescentis ATCC 15703 treatment can attenuate the major characteristic of allergic asthma, eosinophil airway influx, in Balb/c but not B6 mice. These results suggest that oral treatment with this specific live bacterial strain may have therapeutic potential for the treatment of allergic airway disease, although its effect is mouse-strain-dependent.

摘要

过敏性哮喘是一种慢性疾病,主要特征为嗜酸性粒细胞炎症和气道重塑。许多研究表明,过敏性个体的肠道微生物群与非过敏性个体不同。虽然双歧杆菌水平较高与健康个体有关,但双歧杆菌属青少年 ATCC 15703,一种肠道细菌,在一些临床研究中与过敏性个体有关。双歧杆菌属青少年 ATCC 15703 与哮喘或过敏的关系尚未得到充分阐明,其作用可能取决于宿主的遗传特征或疾病状态。为了阐明这个问题,我们评估了预防性双歧杆菌属青少年 ATCC 15703 治疗对两种遗传不同的小鼠品系(Balb/c 和 C57BL/6(B6))实验性过敏性气道炎症的作用。Balb/c 小鼠比 B6 小鼠更容易发生过敏反应。双歧杆菌属青少年 ATCC 15703 的预防性口服治疗调节了实验性过敏性气道炎症,特别是在 Balb/c 小鼠中,气道中的嗜酸性粒细胞水平降低。B6 小鼠没有表现出任何明显的嗜酸性粒细胞变化,但总白细胞和中性粒细胞向气道的流入增加。这些细菌在实验性过敏性小鼠中的有益作用的机制可能涉及细菌代谢产物,因为死细菌不能模拟活双歧杆菌属青少年 ATCC 15703 减弱嗜酸性粒细胞向气道流入的能力。总之,预防性口服双歧杆菌属青少年 ATCC 15703 治疗可以减轻 Balb/c 但不是 B6 小鼠过敏性哮喘的主要特征,即嗜酸性粒细胞气道浸润。这些结果表明,这种特定的活菌株的口服治疗可能对过敏性气道疾病的治疗具有治疗潜力,尽管其作用依赖于小鼠品系。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验